Ayer en #FarmaIMID2023 …
What’s 🆕?
✍🏻en Reumatología:
✅ Tocilizumab biosimilar
✅ Bimekizumab - EspA (💶 en estudio)
✅ Anifrolumab - LES
✅ Voclosporina - nefritis lúpica
✅ Avacopan - vasculitis ANCA+
Last Word On Spurs I mean won't be hard to figure them out they will be the only ones supporting Spurs
#RNL2024 Dr. John Cush
April Armstrong, MD MPH
Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs
- Fast onset
- High efficacy with 2/3 PASI 100 by wk 16 (BE READY)